The Brave New World of Function-Promoting Anabolic Therapies: Testosterone and Frailty
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Physical function is an excellent marker of an individual’s health (1). Limitations in physical function are an important public health problem because of their high prevalence and their association with adverse health outcomes, including the increased risk of disability, poor quality of life, hospitalization, and mortality (2, 3). In the USA alone, 12–14% of the noninstitutionalized population—approximately 35–38 million people—have a disability due to a chronic health condition (4). For people over age 65 yr, 35 to 40% experience activity limitations or disability. Because the U.S. population is aging, the percentage of population aged 65 yr or over will increase from 12% in 2000 to 20% in 2030—to more than 69 million. The number of people 85 or older is expected to grow from 3 million (2.1%) to 6.2 million (3.4%) in the United States alone. The majority of individuals who reach this age will experience some limitation in function (4, 5). The costs of support services, lost productivity associated with disabling conditions, and the impact of disability on an individual’s quality of life will have enormous societal consequences (6). Currently, the practicing physicians have few therapeutic choices for the treatment of older individuals with functional limitations and physical disability. Exercise, physical rehabilitation, and behavioral modalities have had limited impact at a population level. Therefore, there is growing need for developing pharmacological function promoting therapies for the treatment of functional limitations. It has become apparent that a small number of intersecting signaling pathways are crucial for regulating muscle growth through their effects on ribosomal protein translation (AkT/mammalian target of rapamycin pathway), mesenchymal progenitor cell differentiation (Wnt and Smad signaling), and muscle protein degradation (ubiquitin-proteasome pathway and the FoXo family of transcription factors). Pharmacophores that selectively modulate these signaling pathways, such as androgens, myostatin antagonists, and GH/IGF-I mimetics are being explored for their potential as function-promoting anabolic therapies; of these, androgens are the farthest along in development. The idea that androgens have anabolic effects on the skeletal muscle is not new. Athletes and recreational body builders who abuse androgens do so because of the widely held perception that androgens increase muscle mass, muscle strength, and athletic performance. However, systematic investigations of androgens as function-promoting therapies have been limited largely to the past 15 yr (7). Epidemiological studies have shown that circulating testosterone levels are associated with skeletal muscle mass, muscle strength, and self-reported as well as performance-based measures of physical function (8–10). Cawthon et al. (11) reported in a recent issue of the Journal that low levels of bioavailable testosterone in men participating in the Osteoporotic Fractures in Men Study (MrOS) were associated independently with worse frailty status. In longitudinal analysis, the men in the lowest quartile of bioavailable testosterone levels had approximately 1.5-fold higher odds of greater frailty status 4.1 yr later (11). However, neither total nor free testosterone levels were associated with frailty status. Mohr et al. (12) in a separate analysis of the data from the Massachusetts Male Aging Study (MMAS) also found no significant association of total or free testosterone levels with overall frailty status. However, in the MMAS, total testosterone levels were associated with some frailty components—grip strength and physical activity—but not with other components such as exhaustion, slow walking, or weight loss (12). In light of the known effects of testosterone on muscle mass and strength, it is not surprising that testosterone levels would be associated with frailty components that are more tightly linked to skeletal muscle mass and strength. Undoubtedly, frailty is a heterogeneous construct, and not all of its components share a common biological or pathophysiological basis or have the same prognostic significance (13). In this issue of the Journal, Srinivas-Shankar et al. (14) report the results of the first randomized clinical trial of the effects of testosterone therapy in older men with one or more components of the frailty syndrome, total testosterone less than 12 nmol/liter, or free testosterone less than 250 pmol/liter. The study had several features of good clinical trial design: randomization, blinding of subjects and investigators, parallel group design, and inclusion of a placebo group as the reference for comparison (14). Unlike some other important studies that did not achieve robust increments in testosterone concentrations (15, 16), Srinivas-Shankar et al. (14) adjusted the testosterone dose to achieve testosterone concentrations in the target range. Testosterone therapy was associated with greater improvements in isokineti
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Physical performance measures in the clinical setting
Studenski, S., Perera, S., Wallace, D., Chandler, J. M., Duncan, P. W., Rooney, E., Fox, M., & Guralnik, J. M. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2003.51104.x · Cited by 1,218 · cited 1×
“Physical function is an excellent marker of an individual’s health (1).”
Newman, A. B., Simonsick, E. M., Naydeck, B. L., Boudreau, R. M., Kritchevsky, S. B., Nevitt, M. C., Pahor, M., Satterfield, S., Brach, J. S., Studenski, S. A., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2018 · Cited by 934
Srinivas-Shankar, U., Roberts, S. A., Connolly, M. J., O'Connell, M. D. L., Adams, J. E., Oldham, J. A., & Wu, F. C. W. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1251 · Cited by 629 · cited 6×
“(14), which represents the first randomized clinical trial of testosterone in men with frailty or intermediate frailty.”
InfluentialDHEA in elderly women and DHEA or testosterone in elderly men.
Nair, K. S., Rizza, R. A., O'Brien, P., Dhatariya, K., Short, K. R., Nehra, A., Vittone, J. L., Klee, G. G., Basu, A., Basu, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054629 · Cited by 566 · cited 1×
“Unlike some other important studies that did not achieve robust increments in testosterone concentrations (15, 16), Srinivas-Shankar et al.”
Emmelot-Vonk, M. H., Verhaar, H. J. J., Nakhai Pour, H. R., Aleman, A., Lock, T. M. T. W., Bosch, J. L. H. R., Grobbee, D. E., & van der Schouw, Y. T. (2008) · JAMA · doi:10.1001/jama.2007.51 · Cited by 518
Prognostic significance of potential frailty criteria
Rothman, M. D., Leo‐Summers, L., & Gill, T. M. (2008) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2008.02008.x · Cited by 428
Sex Hormones and Frailty in Older Men: The Osteoporotic Fractures in Men (MrOS) Study
Cawthon, P. M., Ensrud, K. E., Laughlin, G. A., Cauley, J. A., Dam, T.-T. L., Barrett-Connor, E., Fink, H. A., Hoffman, A. R., Lau, E., Lane, N. E., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0417 · Cited by 157
Storer, T. W., Woodhouse, L., Magliano, L., Singh, A. B., Dzekov, C., Dzekov, J., & Bhasin, S. (2008) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2008.01927.x · Cited by 145
Self-citationWoodhouse, L. J., Reisz-Porszasz, S., Javanbakht, M., Storer, T. W., Lee, M., Zerounian, H., & Bhasin, S. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00536.2002 · Cited by 73 · cited 1×
“Because gains in skeletal muscle mass and strength are correlated with testosterone dose and testosterone concentrations (17, 18), it may be necessary to raise serum testosterone concentrations to even higher levels than those achieved in this trial to realize clinically meaningful gains in muscle mass and strength; t…”
Self-citation
Cited by
Ng Tang Fui, M., Prendergast, L. A., Dupuis, P., Raval, M., Strauss, B. J., Zajac, J. D., & Grossmann, M. (2016) · BMC Medicine · doi:10.1186/s12916-016-0700-9 · Cited by 124
O'Connell, M. D. L., Roberts, S. A., Srinivas-Shankar, U., Tajar, A., Connolly, M. J., Adams, J. E., Oldham, J. A., & Wu, F. C. W. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1167 · Cited by 98
“An alternative option is the use of pharmacological anabolic interventions (5).”
BackgroundNg Tang Fui, M., Hoermann, R., Zajac, J. D., & Grossmann, M. (2017) · Clinical Endocrinology · doi:10.1111/cen.13385 · Cited by 37
Wiren, K. M., Hashimoto, J. G., & Zhang, X.-W. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23288 · Cited by 5
Metadata
- Authors
- Bhasin, S.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2010-02-01
- Volume
- 95
- Issue
- 2
- Pages
- 509-511
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2074941721
- Cited by
- 33
- References
- 9
- FWCI
- 3.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.